Reading TLSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TLSI free→Reading TLSI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TLSI free→QuarterlyIQ Insights · TLSI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Conditions. On May 12, 2026 , TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The Company is grateful for Ms. Devlin’s contributions. As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an offer letter with Dr. Richard Marshall for the position of Chief Medical Officer. Dr. Marshall’s employment is expected to start on June 29, 2026 with an annual base salary of $525,000 and a sign on bonus of $250,000. Dr. Marshall will also be eligible for an annual bonu…
Results of Operations and Financial Conditions. On March 5, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Entry into a Material Definitive Agreement. On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. (b) On February 3, 2026, Dr. Arjun “JJ” Desai informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, effective immediately. Dr. Desai’s resignation is not a result of any disagreement with the Company on any matter relating to the Company’s…
Results of Operations and Financial Conditions. On January 12, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025 and 2026 revenue guidance. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Secti…
Results of Operations and Financial Conditions. On November 13, 2025, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended September 30, 2025. A copy of the press is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. (b) On September 30, 2025, Sean Murphy informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board and the Science and Technology Committee of the Board, effective immediately. Mr. Murphy’s resignation is not a result of any disagreement with the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of TriSalus Life Sciences, Inc. (the “Company”), approved an increase in the annual compensation of Mr. David Patience, the Company’s Chief Financial Officer, from the he $450,000 annual base salary indicated in his Executive Employment Agreement…
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Material Modifications to Rights of Security Holders.
Other Events. On June 23, 2025, TriSalus Life Sciences, Inc. (the “Company”), announced the commencement of (i) its exchange offer (the “Offer”) identified in the Prospectus/Offer to Exchange (as defined below) the opportunity to receive that number of shares of common stock of the Company, par value $0.0001 per share (“Common Stock”) equal to the quotient of (i) the sum of (a) the Liquidation Preference (as defined in the Certificate of Designations of the Preferred Stock (the “Certificate o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. On May 23, 2025, TriSalus Life Sciences, Inc. (the “Company”) and James Young, the Company’s Chief Financial Officer, entered into an Agreement and Release (the “Agreement”) whereby Mr. Young resigned from the Company for personal reasons, effective May 30, 2025. Pursuant to the Agreement, Mr. Young will be paid an amount equal to six (6) months a…
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 30, 2025, TriSalus Life Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors named therein (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 5,500,000 shares (the “Shares”) of the Company’s common stock, p…
by reference. The information in this Item 7.01, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act. Cautionary Statement Regarding Forward-Looking Statements Statements…
Based in part upon the representations of the Purchasers in the Purchase Agreement, the offering and sale of the Shares described above are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or…
Results of Operations and Financial Condition. Full financial results for the quarter ended March 31, 2025 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $9.2 million in the first quarter of 2025. This represents growth of approximately 42% versus the first quarter of 2024. The preliminary results set forth above are unaudited, are based on management’s initial review of the Company’s…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. (b) On April 20, 2025, George Kelly Martin informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately. Mr. Martin’s resignation is not a result…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. (b) On April 16, 2025, Liselotte Hyveled informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of her decision to resign from her position as a member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, effective immediately. Ms.…
of this Current Report on Form 8-K of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. (b) On February 19, 2025, Sean Murphy notified TriSalus Life Sciences, Inc. (the “Company”) of his intent to step down as an officer and employee of the Company effective February 28, 2025. Mr. Murphy will continue in his role as a member of the Board of Directors of the Company. SIGNATURES Pursuant to the requirements of the Securities Exchange A…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On February 18, 2025, the closing for the Second Tranche occurred and the Borrower received $10 million pursuant to the Second Tranche. The Second Tranche loan will mature on April 30, 2029. The Third Tranche remains available pursuant to the terms of the Credit Agreement. In connection with the closing of the Second Tranche and pursuant to the Credit Agreement, on February 18, 2…
The issuance of shares of the Company’s common stock underlying the Warrants will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), and Rule 506 of Regulation D thereunder. The Warrants and the underlying shares of the Company’s common stock have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exempti…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'full' to 'inexpensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.